)| PMID |
15691215 ( ) |
|---|---|
| Title | Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. |
| Abstract | Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which no cure or effective treatment presently exists. Many different types of drugs have been tested; most are based on various hypotheses of mechanisms for neuronal death, including oxidative damage, loss of trophic factor support, glutamate-mediated excitotoxicity, and chronic inflammation. The discovery that a small percentage of ALS cases are familial and involve mutation in a superoxide dismutase gene (SOD1) led to the development of transgenic mouse models presently widely used for testing possible drugs. Mutations in the vascular endothelial growth factor gene (VEGF) also appear to be involved. Riluzole, an inhibitor of glutamate release and the only agent presently approved for clinical use, only extends survival by a few months. A number of trophic factors, anti-inflammatory agents, and inhibitors of oxidative stress have been reported to prolong survival in mouse models and some are now in clinical trials. Gene transfer of VEGF or glial cell-line derived neurotrophic factor, anti-inflammatory COX-2 inhibitors, and minocycline have had particularly promising results in mice. No breakthrough has yet occurred and present thinking is that combinations of drugs may be required to slow the multifactorial neurodegeneration process effectively. Columbia, Vancouver, British Columbia, Canada. mcgeer@interchange.ubc.ca therapy |
NOTE: Color highlight is limited to the abstract and SciMiner text-mining mode. If you see much more identified targets below from "Targets by SciMiner Summary" and "Targets by SciMiner Full list", they may have been identified from the full text.
Targets by SciMiner Summary
| HUGO ID | Symbol | Target Name | #Occur | ActualStr |
|---|---|---|---|---|
| 12680 | VEGFA | vascular endothelial growth factor A | 3 | VEGF | vascular endothelial growth factor | |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | 2 | SOD1 | superoxide dismutase | |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | 2 | COX-2 | cox 2 | |
| 4232 | GDNF | glial cell derived neurotrophic factor | 1 | glial cell line derived neurotrophic factor | |
Targets by SciMiner Full list
| HUGO ID | Symbol | Name | ActualStr | Score | FlankingText |
|---|---|---|---|---|---|
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 1.4 | familial and involve mutation in a superoxide dismutase gene (SOD1) SOD1 led to the development of transgenic mouse models presently widely |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 4.1 | Mutations in the vascular endothelial growth factor gene (VEGF) VEGF also appear to be involved |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 4.1 | Gene transfer of VEGF or glial cell-line derived neurotrophic factor anti-inflammatory COX-2 inhibitors and |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | COX-2 | 1.0 | transfer of VEGF or glial cell-line derived neurotrophic factor anti-inflammatory COX-2 inhibitors and minocycline have had particularly promising results in mice |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | superoxide dismutase | 1.0 | the discovery that a small percentage of als cases are familial and involve mutation in a superoxide dismutase gene sod1 led to the development of transgenic mouse models presently widely used for testing possible drugs. |
| 12680 | VEGFA | vascular endothelial growth factor A | vascular endothelial growth factor | 1.0 | mutations in the vascular endothelial growth factor gene vegf also appear to be involved. |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | cox 2 | 1.0 | gene transfer of vegf or glial cell line derived neurotrophic factor anti inflammatory cox 2 inhibitors and minocycline have had particularly promising results in mice. |
| 4232 | GDNF | glial cell derived neurotrophic factor | glial cell line derived neurotrophic factor | 1.0 | gene transfer of vegf or glial cell line derived neurotrophic factor anti inflammatory cox 2 inhibitors and minocycline have had particularly promising results in mice. |